Yahoo Finance

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology. Its mission is to realize the potential of cell engineering to provide patients with ...
Yahoo Finance

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell ...
Nasdaq

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Novel engineered iPS cell line to be evaluated by Lineage for potential development of cell transplant therapies for central nervous system diseases under collaboration initiated in early 2023 Lineage ...
Nasdaq

Eterna Therapeutics Appoints Dr. Elena Ratner to Board of Directors to Enhance Focus on Ovarian Cancer Research

Eterna Therapeutics has appointed Dr. Elena Ratner to its Board of Directors to lead the company's initiatives against ovarian cancer. Dr. Ratner, an expert in obstetrics and gynecology, aims to ...
Benzinga.com

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics

Lineage Cell Therapeutics Inc LCTX has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and ...